HSIC

Business Context and Reporting Period

Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: Henry Schein is a leading distributor of healthcare products and services to office-based practitioners (dental, medical, animal health) in North America and Europe. Operations are divided into two segments: Healthcare Distribution and Technology.

Key Financial Metrics

Note: Q1 2006 Net Income included a $19.4 million after-tax loss from discontinued operations (Hospital Supply Business sale), which is not present in Q1 2007.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 14.8% year-over-year. Growth was driven by 12.4% local currency growth (4.2% organic, 8.2% acquisitions) and 2.4% foreign currency exchange impact.
• Segment Performance:
  • Dental: Sales up 16.7% (driven by consumables and equipment growth).
  • Medical: Sales up 11.3% (acquisitions offset by lower pharmaceutical sales).
  • International: Sales up 15.1% (driven by 9.0% currency impact and 6.1% local currency growth).
  • Technology: Sales up 24.6% (driven by software and financial services).
• Profitability: Operating income rose 21.3% to $73.9 million. Gross margin improved to 29.5% due to favorable sales mix and margin management in the distribution segment.
• Cash Flow: Net cash used in operating activities was $33.9 million, an improvement of $4.1 million compared to the prior year, primarily due to timing of working capital receipts and payments.

Outlook, Risks, and Unusual Items

• Capital Allocation: The company repurchased $30.7 million of common stock in the quarter. As of March 31, 2007, $140.5 million remained available under authorized repurchase programs. Capital expenditures for the remainder of the fiscal year are expected to be between $35.0 million and $40.0 million.
• Investments: The company loaned $10.1 million to D4D Technologies, LLC, with an additional $5.7 million expected in 2007. Equity investments totaling $27.7 million are contingent on operational milestones.
• Debt Structure: Total debt remained stable. The company holds $240 million in convertible senior notes (3.0% interest, due 2034) and various senior notes with fixed and variable rates. A $300 million revolving credit facility is available with no borrowings outstanding as of period end.
• Risks: Key risks include industry consolidation, dependence on third-party manufacturers, regulatory changes, foreign currency fluctuations, and the impact of cost containment trends in healthcare.
• Legal Proceedings: Approximately 15 product liability cases are pending; management believes these are covered by insurance or indemnification and will not have a material adverse effect.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the comparability of Net Income by noting the $19.4 million loss from discontinued operations in Q1 2006, which significantly depressed prior-year earnings.
• Acquisition Contribution: Assess the sustainability of growth, as 8.2% of total sales growth and significant portions of segment growth were attributed to acquisitions.
• Working Capital Trends: Monitor the $33.9 million cash outflow from operations, driven by changes in accounts payable and receivable, to ensure it is not a recurring trend.
• Convertible Debt: Review the terms of the $240 million convertible notes, specifically the conversion triggers and the company's ability to satisfy the cash portion of conversion obligations.
• Stock Repurchases: Confirm the remaining $140.5 million authorization and the pace of buybacks relative to cash flow generation.